- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03895814
Protective Step Training in Parkinson's Disease
Protective Step Training in People With Parkinson's Disease and Postural Disturbances
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project contains 3 aims: Aims 1 and 2 address the primary goal of this project: Determining the effectiveness of protective step training. Aim 1 will test whether perturbation training can improve protective stepping in people with PD with postural dysfunction. Aim 2 will test whether improvements are retained over 2 months and generalize to untrained perturbation tasks (which may be important for real world situations). Importantly, investigators will also gather exploratory data regarding the effect of perturbation training on falls. Aim 3 addresses the secondary goal of this project: Determining for whom protective step training is most beneficial. Aim 3 will relate behavioral factors and neuroimaging outcomes to the magnitude of improvement in protective stepping. All aims will be tested in people with PD who have postural disturbances.
To complete these aims, participants will undergo 12 visits to the laboratory over the course of about 5 months. These will include 6 "training visits" over the course of 2 weeks, surrounded by 6 "assessment" visits before and after the training. During assessment visits, investigators will assess the ability to step quickly in response to a loss of balance (e.g. a slip), as well as thinking assessments and, if eligible, investigators will complete an MRI. During training visits, investigators will train the ability to step quickly in response to a slip.
In this study, participants will serve as their own controls. As such, there is no randomization to multiple groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neurologist diagnosed PD
- Postural Instability / Gait Dysfunction (PIGD)
- Ability to stand unaided for 5 minutes
Exclusion Criteria:
- non-PD related neurological pathology
- orthopedic impairments affecting balance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Multi-baseline Step Training
Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week "protective step training period.
Participants will also be assessed 2 months later at a follow-up visit.
|
Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stepping performance, measured as Margin of Stability (MOS)
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
MOS: Distance between the extrapolated center of mass and base of support at first foot contact after the slip
|
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stepping performance, measured as First Step Length
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
Step Length: Length of the first step after the slip
|
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
|
Stepping performance, measured as First Step Latency
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
Step Latency: Time taken to lift the foot off the ground after the slip start
|
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
|
|
Cognition, measured as the total score on the "SCales for Outcomes in PArkinson's disease-COGnition" (SCOPA-COG)
Time Frame: Baseline
|
SCOPA-COG: This scale characterizes cognitive capacity of several domains, and was developed specifically for people with PD.
Range: 0-43 (higher score reflects better cognitive capacity).
Subscales/domains are calculated, and the *total* score is calculated as the sum of each subscale.
|
Baseline
|
|
Structural brain connectivity between the cortex (supplementary motor area), and basal ganglia (striatum)
Time Frame: Baseline
|
Diffusion Tensor Imaging data (collected via MRI), will be collected and analyzed to characterize the structural connectivity specifically between the cortex and basal ganglia.
|
Baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retention of stepping improvement (measured as Margin of Stability; MOS) over 2 months
Time Frame: Change in MOS score from Baseline to Follow-up (10 weeks between collections)
|
Characterization of whether MOS changes observed over training period are retained at follow-up.
|
Change in MOS score from Baseline to Follow-up (10 weeks between collections)
|
|
Generalization of stepping improvement (measured as Margin of Stability; MOS)
Time Frame: Change in MOS score from Baseline 2 to Post (2 weeks between collections)
|
Characterize whether training impacts MOS of an untrained reactive stepping task
|
Change in MOS score from Baseline 2 to Post (2 weeks between collections)
|
|
Fall frequency
Time Frame: Change in the number of falls during baseline (2 months) and follow-up (2 months) periods.
|
Number of falls will be recorded via fall calendar in the 2 month period prior to training (baseline) and the 2 month period following training (post)
|
Change in the number of falls during baseline (2 months) and follow-up (2 months) periods.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel Peterson, Arizona State University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00008325
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.